A guide to immunotherapy for COVID-19

Frank L. van de Veerdonk; Evangelos Giamarellos-Bourboulis; Peter Pickkers; Lennie Derde; Helen Leavis; Reinout van Crevel; Job J. Engel; W. Joost Wiersinga; Alexander P.J. Vlaar; Manu Shankar-Hari; Tom van der Poll; Marc Bonten; Derek C. Angus; Jos W.M. van der Meer; Mihai G. Netea

doi:10.1038/s41591-021-01643-9

A guide to immunotherapy for COVID-19

Frank L. van de Veerdonk^*, Evangelos Giamarellos-Bourboulis, Peter Pickkers, Lennie Derde, Helen Leavis, Reinout van Crevel, Job J. Engel, W. Joost Wiersinga, Alexander P.J. Vlaar, Manu Shankar-Hari, Tom van der Poll, Marc Bonten, Derek C. Angus, Jos W.M. van der Meer, Mihai G. Netea^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

109 Citations (Scopus)

Abstract

Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.

Original language	English
Pages (from-to)	39-50
Number of pages	12
Journal	Nature Medicine
Volume	28
Issue number	1
Early online date	21 Jan 2022
DOIs	https://doi.org/10.1038/s41591-021-01643-9
Publication status	Published - Jan 2022

Keywords

Antibodies, Monoclonal/therapeutic use
Antibodies, Monoclonal, Humanized/therapeutic use
Antibodies, Neutralizing/therapeutic use
Anticoagulants/therapeutic use
Azetidines/therapeutic use
Bradykinin/analogs & derivatives
Bradykinin B2 Receptor Antagonists/therapeutic use
COVID-19/immunology
Complement Inactivating Agents/therapeutic use
Dexamethasone/therapeutic use
Drug Combinations
Factor Xa Inhibitors/therapeutic use
Glucocorticoids/therapeutic use
Heparin/therapeutic use
Humans
Hydrocortisone/therapeutic use
Imatinib Mesylate/therapeutic use
Immunization, Passive
Immunologic Factors/therapeutic use
Immunomodulation
Interferon beta-1a/therapeutic use
Interferon beta-1b/therapeutic use
Interferon-gamma/therapeutic use
Interleukin 1 Receptor Antagonist Protein/therapeutic use
Kallikrein-Kinin System
Piperidines/therapeutic use
Protein Kinase Inhibitors/therapeutic use
Purines/therapeutic use
Pyrazoles/therapeutic use
Pyrimidines/therapeutic use
SARS-CoV-2
Sulfonamides/therapeutic use
COVID-19 Serotherapy

Access to Document

10.1038/s41591-021-01643-9

Cite this

van de Veerdonk, F. L., Giamarellos-Bourboulis, E., Pickkers, P., Derde, L., Leavis, H., van Crevel, R., Engel, J. J., Wiersinga, W. J., Vlaar, A. P. J., Shankar-Hari, M., van der Poll, T., Bonten, M., Angus, D. C., van der Meer, J. W. M., & Netea, M. G. (2022). A guide to immunotherapy for COVID-19. Nature Medicine, 28(1), 39-50. https://doi.org/10.1038/s41591-021-01643-9

@article{c522967507e14807b1f50c3967157f76,

title = "A guide to immunotherapy for COVID-19",

abstract = "Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.",

keywords = "Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Neutralizing/therapeutic use, Anticoagulants/therapeutic use, Azetidines/therapeutic use, Bradykinin/analogs & derivatives, Bradykinin B2 Receptor Antagonists/therapeutic use, COVID-19/immunology, Complement Inactivating Agents/therapeutic use, Dexamethasone/therapeutic use, Drug Combinations, Factor Xa Inhibitors/therapeutic use, Glucocorticoids/therapeutic use, Heparin/therapeutic use, Humans, Hydrocortisone/therapeutic use, Imatinib Mesylate/therapeutic use, Immunization, Passive, Immunologic Factors/therapeutic use, Immunomodulation, Interferon beta-1a/therapeutic use, Interferon beta-1b/therapeutic use, Interferon-gamma/therapeutic use, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Kallikrein-Kinin System, Piperidines/therapeutic use, Protein Kinase Inhibitors/therapeutic use, Purines/therapeutic use, Pyrazoles/therapeutic use, Pyrimidines/therapeutic use, SARS-CoV-2, Sulfonamides/therapeutic use, COVID-19 Serotherapy",

author = "{van de Veerdonk}, {Frank L.} and Evangelos Giamarellos-Bourboulis and Peter Pickkers and Lennie Derde and Helen Leavis and {van Crevel}, Reinout and Engel, {Job J.} and Wiersinga, {W. Joost} and Vlaar, {Alexander P.J.} and Manu Shankar-Hari and {van der Poll}, Tom and Marc Bonten and Angus, {Derek C.} and {van der Meer}, {Jos W.M.} and Netea, {Mihai G.}",

note = "Publisher Copyright: {\textcopyright} 2022, Springer Nature America, Inc.",

year = "2022",

month = jan,

doi = "10.1038/s41591-021-01643-9",

language = "English",

volume = "28",

pages = "39--50",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - A guide to immunotherapy for COVID-19

AU - van de Veerdonk, Frank L.

AU - Giamarellos-Bourboulis, Evangelos

AU - Pickkers, Peter

AU - Derde, Lennie

AU - Leavis, Helen

AU - van Crevel, Reinout

AU - Engel, Job J.

AU - Wiersinga, W. Joost

AU - Vlaar, Alexander P.J.

AU - Shankar-Hari, Manu

AU - van der Poll, Tom

AU - Bonten, Marc

AU - Angus, Derek C.

AU - van der Meer, Jos W.M.

AU - Netea, Mihai G.

PY - 2022/1

Y1 - 2022/1

N2 - Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.

AB - Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.

KW - Antibodies, Monoclonal/therapeutic use

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Antibodies, Neutralizing/therapeutic use

KW - Anticoagulants/therapeutic use

KW - Azetidines/therapeutic use

KW - Bradykinin/analogs & derivatives

KW - Bradykinin B2 Receptor Antagonists/therapeutic use

KW - COVID-19/immunology

KW - Complement Inactivating Agents/therapeutic use

KW - Dexamethasone/therapeutic use

KW - Drug Combinations

KW - Factor Xa Inhibitors/therapeutic use

KW - Glucocorticoids/therapeutic use

KW - Heparin/therapeutic use

KW - Humans

KW - Hydrocortisone/therapeutic use

KW - Imatinib Mesylate/therapeutic use

KW - Immunization, Passive

KW - Immunologic Factors/therapeutic use

KW - Immunomodulation

KW - Interferon beta-1a/therapeutic use

KW - Interferon beta-1b/therapeutic use

KW - Interferon-gamma/therapeutic use

KW - Interleukin 1 Receptor Antagonist Protein/therapeutic use

KW - Kallikrein-Kinin System

KW - Piperidines/therapeutic use

KW - Protein Kinase Inhibitors/therapeutic use

KW - Purines/therapeutic use

KW - Pyrazoles/therapeutic use

KW - Pyrimidines/therapeutic use

KW - SARS-CoV-2

KW - Sulfonamides/therapeutic use

KW - COVID-19 Serotherapy

UR - http://www.scopus.com/inward/record.url?scp=85123401345&partnerID=8YFLogxK

U2 - 10.1038/s41591-021-01643-9

DO - 10.1038/s41591-021-01643-9

M3 - Review article

C2 - 35064248

SN - 1078-8956

VL - 28

SP - 39

EP - 50

JO - Nature Medicine

JF - Nature Medicine

IS - 1

ER -

A guide to immunotherapy for COVID-19

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this